Express Scripts Inc.
1 Express Way
120 articles with Express Scripts Inc.
Pet specialty retailer supports commitment to total pet care and wellness with convenient, accessible pet prescriptions available online for doorstep delivery
New National Preferred Flex Formulary provides employers and health plans a pathway to cover lower list price products, help deliver lower member out-of-pocket costs, and reduce reliance on brand rebates.
myMatrixx®, a leader in pharmacy services for workers' compensation programs and a subsidiary of Express Scripts Holding Company (NASDAQ: ESRX), announces the release of myDataSenseSM, an innovative and customizable digital analytics tool that will help drive patient safety and savings.
Express Scripts, a leading pharmacy benefits management company, continues to show its commitment to the region by adding 115 new positions at its Tempe facilities.
Express Scripts Holding Company announced consolidated 2018 third quarter net income of $1,071.6 million or $1.89 per diluted share.
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
Thousand Oaks-based Amgen will reduce the price of its anti-cholesterol drug Repatha by 60 percent to $5,850 per year as part of a move to improve affordability by lowering patient copays, the company announced Wednesday.
Express Scripts' Innovative Advanced Opioid Management Solution Shifts First-Time Opioid Users to Safer, Short-Term Prescriptions
Results Align with U.S. Centers for Disease Control & Prevention Recommendations
National Drug Purchasing Coalition - member companies include PepsiCo, Inc. and ExxonMobil - and Express Scripts Team Up to Create New Pharmacy Benefit Design for Greater Performance Accountability, Transparency, and Alignment
Greater Transparency: Clients Pay the Same as Express Scripts Does for Prescription Drugs
Industry first SafeGuardRx Migraine Care Value Program Brings Affordability to Migraine Prevention and Treatment for Patients and Payers
With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.
Express Scripts Holding Company announced today its intention to release its 2018 third quarter financial results on Wednesday, October 31, 2018, after the market closes. Management will not be holding a conference call to review results.
“President Trump is taking historic action to bring patients more transparency through consumer advertising,” Azar said in a speech. “We are proposing to require American drug companies for the first time ever to include in their TV advertising the list prices of drugs paid for by Medicare or Med...
Researchers at Johns Hopkins, the University of California, San Diego, and the National Institute of Mental Health grew retinas in petri dishes, and discovered fundamental factors involved in the development of vision and color vision.
Walmart joins CVS and Kroger in the preferred pharmacy network for Express Scripts' popular, low-premium Saver plan, introduced in 2018
Kenneth Frazier, chief executive officer of Merck, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Express Scripts Flattens the Trajectory of the Diabetes Epidemic with SafeGuardRx Diabetes Care Value® Program
- In its first year, the Express Scripts Diabetes Care Value program delivered nearly $43 million savings for plans; reduced heart attack risk in 15 percent of patients
Inside Rx Announces Access to Fertility Services for Uninsured Americans with Freedom FP Fertility Pharmacy
Freedom FP Fertility Pharmacy and Inside Rx are working to connect patients to more affordable and specialized fertility care
9/25/2018Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic.